In the past week, NDRA stock has gone down by -20.36%, with a monthly decline of -28.36% and a quarterly plunge of -53.92%. The volatility ratio for the week is 13.98%, and the volatility levels for the last 30 days are 9.52% for ENDRA Life Sciences Inc The simple moving average for the past 20 days is -23.18% for NDRA’s stock, with a -32.09% simple moving average for the past 200 days.
Is It Worth Investing in ENDRA Life Sciences Inc (NASDAQ: NDRA) Right Now?
The 36-month beta value for NDRA is at 1.03. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NDRA is 10.88M, and currently, shorts hold a 0.45% of that float. The average trading volume for NDRA on March 28, 2024 was 130.65K shares.
NDRA) stock’s latest price update
ENDRA Life Sciences Inc (NASDAQ: NDRA)’s stock price has dropped by -15.74 in relation to previous closing price of 0.97. Nevertheless, the company has seen a loss of -20.36% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-14 that ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Francois Michelon – Chairman and Chief Executive Officer Michael Thornton – Chief Technology Officer Irina Pestrikova – Senior Director, Finance Conference Call Participants Edward Woo – Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.
NDRA Trading at -24.56% from the 50-Day Moving Average
After a stumble in the market that brought NDRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.45% of loss for the given period.
Volatility was left at 9.52%, however, over the last 30 days, the volatility rate increased by 13.98%, as shares sank -26.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.85% lower at present.
During the last 5 trading sessions, NDRA fell by -20.36%, which changed the moving average for the period of 200-days by -42.64% in comparison to the 20-day moving average, which settled at $1.0528. In addition, ENDRA Life Sciences Inc saw -61.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NDRA starting from Thornton Michael Milos, who purchase 15,000 shares at the price of $1.65 back on May 18 ’23. After this action, Thornton Michael Milos now owns 34,139 shares of ENDRA Life Sciences Inc, valued at $24,750 using the latest closing price.
DIGIANDOMENICO ANTHONY, the Director of ENDRA Life Sciences Inc, purchase 83,333 shares at $1.20 during a trade that took place back on May 02 ’23, which means that DIGIANDOMENICO ANTHONY is holding 102,434 shares at $100,000 based on the most recent closing price.
Stock Fundamentals for NDRA
The total capital return value is set at -2.28. Equity return is now at value -154.42, with -119.23 for asset returns.
Based on ENDRA Life Sciences Inc (NDRA), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -24.09. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is 607.67.
Currently, EBITDA for the company is -12.92 million with net debt to EBITDA at 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In conclusion, ENDRA Life Sciences Inc (NDRA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
